<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
-----------------------------------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 14, 1999
Chiron Corporation
- ------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 0-12798 94-2754624
- ------------------------------------------------------------------------------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification No.)
incorporation)
4560 Horton Street, Emeryville, CA 94608
- ------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (510) 655-8730
N/A
- ------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
<PAGE>
ITEM 5. OTHER EVENTS.
Chiron Corporation announced on May 13, 1999 that Sean P. Lance, the
Company's President and Chief Executive Officer, will be named Chairman of
the Board, succeeding William J. Rutter, Ph.D. The Company also announced
that Raymund Breu, Ph.D., the chief financial officer of Novartis AG, has
been elected to its Board of Directors, replacing Alex Krauer, Ph.D.,
Novartis' former chairman. Sean Lance will chair the Board effective May 14,
1999. Dr. Rutter, one of the Company's founders and its Chairman since its
inception in 1981, will remain on the Board of Directors and act as an
advisor to Mr. Lance.
2
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
CHIRON CORPORATION
Date: May 14, 1999 By: /s/ William G. Green
---------------------------
William G. Green
Senior Vice President,
General Counsel and
Secretary
3
